JPRN-UMIN000016337已完成未知
Randomized Controlled Trial for H.pylori first line eradication therapy considering clarithromycin resistance: PCAB vs PPI - PCAB-based H.pylori first line eradication study (CAP study)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 147
研究概览
简要总结
The ITT and PP eradication rates(ER) of V-AC in the CAM-susceptible H.pylori-infected patients were 87.3% (95%CI: 75.5-94.7%) and 88.9% (77.4-95.8%). The respective ER of PPI-AC were 76.5% (62.5-87.2%) and 86.7% (73.2-94.9%). No significant difference was observed between the groups in ITT(P = .21) or PP (P = .77) analyses. The questionnaire scores did not differ significantly between the groups. Both the ITT and PP ER of V-AC in the CAM-resistant patients were 82.9% (67.9%- 92.8%).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •Past history of taking eradication therapy. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Severe liver dysfunction, Severe renal dysfunction, Severe heart dysfunction. Patients who are disqualified for the study by physicians.
研究者
相似试验
招募中
不适用
Helicobacter pylori(HP) eradication: a randomized prospective study of triple therapy with or without EupatiliDiseases of the digestive systemKCT0001528Chung-Ang Univerisity Hospital300
已完成
不适用
PCAB-based H.pylori eradication study for patients with penicillin allergyHelicobacter pylori infectionJPRN-UMIN000016335Yokohama City University Hospital60
已完成
2 期
PCAB-based H.pylori eradication study for patients with penicillin allergy (CAP-pen study)Helicobacter pyloriHelicobacter pylori infectionJPRN-jRCTs031180133Sue Soichiro60
已完成
不适用
Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori EradicationHelicobacter Pylori InfectionNCT01306786The University of Hong Kong800
招募中
4 期
Helicobacter Pylori Eradication and Follow-upHelicobacter Pylori InfectionNCT05061732Shanghai Zhongshan Hospital4,447
